BioSpace News Archive

The American College of Emergency Physicians applauds the U.S. Department of Health and Human Services’ decision to effectively remove the “X-waiver” requirement for physicians, expanding their ability to utilize medication-assisted treatment for patients struggling with opioid use disorder.

Lantern Pharma announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses.

The medical equipment financing market will significantly expand over the next few years with the rising preference of consumers to rent medical devices and equipment.

Tikcro Technologies Ltd. (OTCQB: TIKRF), today reported its financial results for the third quarter ended September 30, 2020 . “We continue to consider businesses for a reverse merger and other corporate alternatives,” said Aviv Boim , CEO of Tikcro. Financial Results for the Third Quarter Ended September 30, 2020 N

2020 full year revenue of €13.5 million, increased by 51 % compared to 2019 (€9 million) As of December 31, 2020, order backlog of €51.7 million, up 35 % compared to December 31, 2019 Cash and cash equivalents of €16.3 million as of December 31, 2020

Cognoa, the leading pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with autism and other behavioral health conditions, today announced the appointment of Eric B. Mosbrooker as Chief Operations Officer.

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that, as part of the previously communicated decision by Metavant not to advance Imeglimin into a Phase 3 program for strategic reasons

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”) is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. (“HaluGen”), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual’s reaction to hallucinogenic drugs.

adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL)

Saama Technologies, Inc. (“Saama”), the #1 AI clinical analytics platform company, announced today that Ian Holmes, Ph.D., has joined its Swiss Board of Directors, effective January 1, 2021.